Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim Prior Auth Policy Update — Part D …
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    Tufts Health One Care (HMO D‑SNP) 2026 Prior Authorization Medical Necessity Guidelines — Part 1 (Formulary/Drugs list)

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Part 1 of the payer's 2026 prior authorization and medical necessity requirements for Tufts Health One Care (HMO D‑SNP) covering multiple Part D drugs and biologics; describes affected products, required medical information, prescriber restrictions, coverage durations, and prerequisite therapy expectations for listed agents.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyTufts Health One Care (HMO D‑SNP) 2026 Prior Authorization Medical Necessity Guidelines — Part 1
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the documented diagnosis and required prior therapy history and prescriber specialty as specified for the requested product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleproducts listed (partial document)
    2 yearstypical coverage duration
    manyrequires prior Part D drug
    common

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    prescriber specialty limits

    Product-specific Coverage Criteria

    Abilify Mycite — Initial Authorization

    Covered when ALL of the following are met:

    Abilify Mycite initial approval: 1) Documented diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia; 2) Documentation of worsening symptoms with oral aripiprazole; 3) Prescribed by a psychiatrist; 4) Coverage duration: 2 years.

    Prerequisite Part D drug required.

    Arikayce — Initial Authorization

    Covered when ALL of the following are met:

    Arikayce criteria: 1) Documented diagnosis of Mycobacterium avium complex (MAC) lung disease; 2) Used as part of a combination antibacterial regimen; 3) Patient did not achieve at least two negative sputum cultures after ≥6 consecutive months of a multidrug background regimen; 4) Prescribed by or in consultation with an infectious disease specialist or pulmonologist; 5) Coverage duration: 2 years.≥6 months

    Prerequisite Part D drug required.

    Balversa — Initial Authorization

    Covered when ALL of the following are met:

    Balversa criteria: 1) Documented diagnosis of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations; 2) Progressed during or following at least one line of prior systemic therapy; 3) Prior treatment with a PD‑1 or PD‑L1 inhibitor OR member not a candidate for PD‑1/PD‑L1 therapy; 4) Prescribed by an oncologist or urologist; 5) Coverage duration: 2 years.

    Prerequisite Part D drug required.

    Selected hematology/oncology drug criteria

    Examples of drug-specific hematology/oncology coverage criteria (selection):

    Venetoclax/CLL or SLL (example): Member must have a documented diagnosis of CLL or SLL.

    From policy: prescriber must be hematologist/oncologist; coverage 2 years.

    MCL eligibility: Member must have documented MCL AND either has received at least one prior therapy OR is previously untreated and ineligible for autologous hematopoietic stem cell transplant.

    From policy: prescriber must be hematologist/oncologist; coverage 2 years.

    Copiktra

    Covered when ALL of the following are met:

    Copiktra initial therapy: 1) Documented diagnosis of relapsed or refractory CLL or SLL; 2) Has received at least two prior therapies; 3) Prescribed by a hematologist or oncologist; 4) Coverage duration: 2 years.

    Prerequisite Part D drug required.

    Cosentyx and indications

    Covered when specified indication-specific criteria are met:

    Cosentyx — Plaque psoriasis: 1) Documented moderate-to-severe plaque psoriasis; 2) Failed or intolerant to at least one topical therapy from the listed classes (e.g., medium/high potency topical corticosteroid, vitamin D analog, tazarotene, calcineurin inhibitor, anthralin, coal tar).

    Prescribed by or in consultation with dermatologist; coverage duration: 2 years; prerequisite Part D drug required.

    Cosentyx — Non-radiographic axial spondyloarthritis: 1) Documented active nr-axSpA with objective signs of inflammation (elevated CRP and/or MRI sacroiliitis); 2) Trial and failure, contraindication, or intolerance to two NSAIDs at maximally indicated doses for at least one month.1 month NSAID trial

    Prescriber specialty specified; coverage duration: 2 years; prerequisite Part D drug required.

    Dupixent

    Covered when ALL of the following are met:

    Dupixent — Atopic Dermatitis: 1) Documented moderate-to-severe atopic dermatitis; 2) Trial and failure, contraindication, or intolerance to a minimum 30-day supply (14 days allowed for topical corticosteroids in sensitive areas) of medium or higher potency topical corticosteroid OR alternative listed topical agents.30 days (14 days for topical corticosteroids in sensitive areas)

    Prescribed by or in consultation with an allergist, dermatologist, immunologist, pulmonologist, or gastroenterologist; coverage duration: 2 years; prerequisite Part D drug required.

    Dupixent — Asthma: 1) Documented moderate-to-severe asthma with eosinophilic phenotype OR oral corticosteroid dependence.

    Prescriber specialty specified; coverage duration: 2 years; prerequisite Part D drug required.

    Emgality

    Covered when ALL of the following are met:

    Emgality initial approval: 1) Documented diagnosis of migraine or episodic cluster headache; 2) Initial approval duration: 6 months; subsequent approval requires clinically significant reduction in migraine days per month or reduction in weekly cluster headache frequency from baseline as determined by prescriber.

    Subsequent approval: life of plan for responders; prerequisite Part D drug not required.

    Everolimus (TBSO) — Required Medical Information

    Covered when ALL of the following are met:

    Everolimus — Advanced HR+ BC: 1) Documented diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer; 2) Member is postmenopausal, is concurrently taking exemestane, AND has documented failure of letrozole or anastrozole.

    Prescriber must be an oncologist; coverage duration: 2 years; prerequisite Part D drug required.

    Everolimus — ARCC: 1) Documented diagnosis of advanced renal cell carcinoma; 2) Disease progression or intolerance following a trial with sorafenib or sunitinib.

    Prescriber must be oncologist; coverage duration: 2 years; prerequisite Part D drug required.

    Everolimus — NET: Documented progressive neuroendocrine tumors of pancreatic origin (pNET) or progressive, well-differentiated, non-functional NET of GI or lung origin that are unresectable, locally advanced or metastatic.

    Prescriber must be oncologist; coverage duration: 2 years; prerequisite Part D drug required.

    Products in chunk 37 — TSC-related and NSCLC

    Covered when specified diagnostic criteria are met:

    TSC — Partial-onset seizures: Documented diagnosis of partial-onset seizures associated with tuberous sclerosis complex (TSC).

    Prescriber must be neurologist or oncologist; coverage duration: 2 years.

    TSC — SEGA: Documented diagnosis of subependymal giant cell astrocytoma (SEGA) associated with TSC and member is not a candidate for surgical resection.

    Prescriber must be neurologist or oncologist; coverage duration: 2 years.

    Exkivity — NSCLC EGFR exon 20 insertion: Documented locally advanced or metastatic NSCLC with EGFR exon 20 insertion and progression on or after platinum-based chemotherapy.

    Prescriber must be oncologist; coverage duration: 2 years.

    Fasenra / Fintepla criteria

    Covered when specified clinical criteria are met:

    Fasenra: Severe eosinophilic asthma despite inhaled corticosteroids plus an additional controller OR eosinophilic granulomatosis with polyangiitis (EGPA).

    Prescriber must be an asthma specialist or rheumatologist; prerequisite Part D drug required; coverage 2 years.

    Fintepla: Documented diagnosis of seizures associated with Dravet syndrome or Lennox‑Gastaut syndrome.

    Prescriber must be a neurologist; coverage 2 years; no prerequisite Part D drug required.

    Fotivda and Fruzaqla criteria

    Covered when specified prior therapy and diagnosis requirements are met:

    Fotivda: Documented relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.

    Prescriber must be an oncologist; coverage 2 years; prerequisite Part D drug required.

    Fruzaqla: Documented metastatic colorectal cancer with prior fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy AND anti-VEGF therapy; if RAS wild-type, anti‑EGFR therapy when appropriate.

    Coverage 2 years; prerequisite Part D drug required.

    Gavreto and Gilotrif criteria

    Covered when specified molecular and disease-stage criteria are met:

    Gavreto: Metastatic RET fusion-positive NSCLC OR advanced/metastatic RET fusion-positive thyroid cancer requiring systemic therapy (radioactive iodine‑refractory if appropriate).

    Prescriber must be an oncologist; coverage 2 years; no prerequisite Part D drug required.

    Gilotrif: Metastatic NSCLC with documented non‑resistant EGFR mutations OR metastatic squamous NSCLC progressed following platinum-based chemotherapy.

    Prescriber must be an oncologist; coverage 2 years; prerequisite Part D drug required.

    GLP-1 agents and diabetes criteria

    Covered when specified diabetes diagnostic or trial criteria are met:

    Type 2 Diabetes — initial: Diagnosis of Type 2 Diabetes confirmed by prescriber documentation OR record of a 90‑day trial with one product from listed drug classes (e.g., metformin, DPP‑4, SGLT2, sulfonylurea).90 days

    Prerequisite Part D drug required; coverage duration 2 years.

    Type 2 Diabetes — reauthorization: Patient demonstrates positive clinical response to therapy.

    Coverage duration 2 years.

    Genotropin (pediatric GHD) criteria

    Covered when ALL of the following are met:

    Genotropin — Pediatric GHD initiation: 1) Not attained epiphyseal closure by X‑ray; 2) Failed to respond to at least two GH stimulation tests; 3) Documented delayed bone age; 4) Height >2 SD below mean; AND appropriate listed diagnoses (e.g., CRI, Turner syndrome).

    Continuation requires documented growth response after 6 months; coverage duration 2 years.

    Haegarda, Hernexeos, and Hyrnuo (HER2-mutant NSCLC) criteria

    Covered when specified diagnostic criteria are met:

    Haegarda: Documented diagnosis of hereditary angioedema (HAE).

    Prescriber must be allergist or immunologist; coverage 2 years; no prerequisite Part D drug required.

    Hernexeos: Non‑squamous NSCLC that is unresectable or metastatic with HER2 (ERBB2) tyrosine kinase domain activating mutations.

    Coverage 2 years; approve continuation of prior therapy; no prerequisite Part D drug required.

    Hyrnuo: Non‑squamous NSCLC, locally advanced or metastatic, with HER2 tyrosine kinase domain activating mutations AND patient has received prior systemic therapy.

    Prescriber must be oncologist; coverage duration 2 years; continuation of prior therapy approved; prerequisite Part D drug required.

    Ibrance (palbociclib) criteria

    Covered when ANY of the following are met:

    Ibrance — with aromatase inhibitor: HR‑positive, HER2‑negative advanced/metastatic breast cancer used in combination with an aromatase inhibitor as initial endocrine‑based therapy.

    Prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Ibrance — with fulvestrant: HR‑positive, HER2‑negative advanced/metastatic breast cancer with progression following endocrine therapy and to be used with fulvestrant.

    Prescriber must be oncologist; coverage 2 years.

    Ibrance — PIK3CA‑mutated endocrine‑resistant disease: Endocrine‑resistant, PIK3CA‑mutated HR‑positive, HER2‑negative locally advanced or metastatic breast cancer with progression following endocrine therapy and to be used with inavolisib.

    Prescriber must be oncologist; coverage 2 years.

    Icatibant criteria

    Covered when ALL of the following are met:

    Icatibant for HAE: 1) Documented diagnosis of hereditary angioedema with history of at least one severe attack in the past 6 months; 2) For HAE Types 1 & 2, diagnosis confirmed by laboratory testing (e.g., low C4, reduced C1 esterase inhibitor level or function).

    Prescriber must be allergist/hematologist/immunologist; will not be approved for acquired angioedema or concurrent ACE inhibitor use; coverage 2 years.

    Iclusig criteria

    Covered when specified diagnostic or mutation criteria are met:

    Iclusig indications: T315I‑positive ALL or Ph+ ALL with no other kinase inhibitor option; CML: T315I‑positive OR accelerated/blast phase with no other kinase inhibitor option OR chronic phase CML with resistance/intolerance to at least two prior kinase inhibitors.

    Prescriber must be hematologist/oncologist; will not be approved for newly diagnosed chronic phase CML; coverage 2 years; prerequisite Part D drug required.

    Idhifa criteria

    Covered when ALL of the following are met:

    Idhifa criteria: Documented diagnosis of relapsed or refractory AML with an IDH2 mutation; prescribed by a hematologist or oncologist; coverage duration: 2 years.

    No prerequisite Part D drug required.

    Imbruvica criteria

    Covered when ANY of the following are met:

    Imbruvica — CLL/SLL: Documented diagnosis of CLL or SLL.

    Prescriber must be hematologist/oncologist/transplant specialist; coverage 2 years; prerequisite Part D drug required.

    Imbruvica — Waldenstrom's: Documented diagnosis of Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.

    Coverage 2 years; prerequisite Part D drug required.

    Imbruvica — cGVHD: Documented diagnosis of chronic graft‑versus‑host disease and trial and failure of one or more lines of systemic therapy.

    Coverage 2 years; prerequisite Part D drug required.

    Increlex criteria

    Covered when ALL of the following are met:

    Increlex criteria: Documented severe primary IGF‑1 deficiency (height SD ≤ −3.0; basal IGF‑1 SD ≤ −3.0), normal/elevated GH or GH gene deletion, and development of neutralizing antibodies to GH; radiographs documenting open epiphyses required for Tanner stage III or greater; age ≥2 years; prescriber endocrinologist; coverage 2 years.

    Not authorized for secondary forms of IGF‑1 deficiency.

    Inluriyo criteria

    Covered when ALL of the following are met:

    Inluriyo criteria: Diagnosis of advanced or metastatic ER‑positive, HER2‑negative breast cancer with ESR1 mutation(s) and disease progressed following at least one line of endocrine therapy; prescribed in combination per product entry; coverage 2 years.

    Approve continuation of prior therapy; prerequisite Part D drug required.

    Inlyta criteria

    Covered when ANY of the following are met:

    Inlyta first‑line: Advanced renal cell carcinoma using Inlyta as first‑line treatment in combination with avelumab or pembrolizumab.

    Prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Inlyta single agent: Advanced renal cell carcinoma using Inlyta as single agent after failure of at least one systemic therapy (e.g., everolimus, Nexavar, sunitinib).

    Prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Inqovi criteria

    Covered when ALL of the following are met:

    Inqovi criteria: Documented diagnosis of myelodysplastic syndromes (MDS) in specified FAB subtypes and IPSS intermediate‑1/2 or high‑risk groups; prescriber hematologist/oncologist; coverage 2 years.

    No prerequisite Part D drug required.

    Inrebic criteria

    Covered when ALL of the following are met:

    Inrebic criteria: Documented diagnosis of intermediate‑2 or high‑risk primary or secondary myelofibrosis; prescriber hematologist/oncologist; coverage 2 years.

    No prerequisite Part D drug required.

    Gefitinib criteria

    Covered when ALL of the following are met:

    Gefitinib criteria: Documented metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; prescriber must be oncologist; coverage 2 years.

    No prerequisite Part D drug required.

    Itovebi criteria

    Covered when ALL of the following are met:

    Itovebi criteria: Locally advanced or metastatic HR‑positive, HER2‑negative breast cancer that is PIK3CA‑mutated; used following recurrence on or after completing adjuvant endocrine therapy and in combination with palbociclib and fulvestrant; coverage 2 years.

    Approve continuation of prior therapy; prerequisite Part D drug required.

    Iwilfin criteria

    Covered when ALL of the following are met:

    Iwilfin criteria: Diagnosis of high‑risk neuroblastoma (HRNB) with at least a partial response to prior multiagent, multimodality therapy including anti‑GD2 immunotherapy; prescriber oncologist; coverage 2 years; continuation of prior therapy approved; prerequisite Part D drug required.

    Jakafi criteria

    Covered when specified disease and treatment‑failure criteria are met:

    Jakafi — Chronic GVHD: Documented chronic graft‑versus‑host disease after failure of one or two lines of systemic therapy.

    Coverage duration 2 years; prerequisite Part D drug required.

    Jakafi — Myelofibrosis: Documented intermediate or high‑risk myelofibrosis (primary, post‑PV, post‑ET).

    Subsequent authorization requires documentation of spleen size reduction or symptomatic improvement; coverage 2 years; prerequisite Part D drug required.

    Jakafi — Polycythemia Vera: Documented polycythemia vera with inadequate response, contraindication, or intolerance to hydroxyurea.

    Coverage 2 years; prerequisite Part D drug required.

    Jakafi — Steroid‑Refractory acute GVHD: Documented steroid‑refractory acute graft‑versus‑host disease.

    Jakafi / Jakafi XR (example entry in chunk 54)

    Covered when product‑specific requirements are documented:

    Jakafi / Jakafi XR (example): Diagnosis of high‑risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti‑GD2 immunotherapy; prescriber must be an oncologist; coverage duration 2 years; continuation of prior therapy approved; prerequisite Part D drug required.

    Example entry from product list.

    Jaypirca (chunk 55)

    Covered when ALL criteria met:

    Jaypirca coverage criteria: Documented diagnosis of one of: chronic GVHD after failure of 1–2 systemic therapies OR intermediate/high‑risk myelofibrosis (primary, post‑PV, post‑ET) OR polycythemia vera with inadequate response/intolerance to hydroxyurea OR steroid‑refractory acute GVHD; prescriber oncologist; coverage 2 years; for myelofibrosis subsequent auth requires documentation of spleen reduction or symptomatic improvement; prerequisite Part D drug required.

    Jubbonti (chunk 56)

    Covered when ALL criteria met:

    Jubbonti coverage criteria: 1) Relapsed or refractory mantle cell lymphoma after ≥2 prior systemic therapies including a BTK inhibitor OR 2) CLL/SLL previously treated with a covalent BTK inhibitor; prescribed by or in consultation with an oncologist; coverage 2 years; prerequisite Part D drug required.

    Jubbonti (denosumab for osteoporosis) (chunk 57)

    Covered when ANY of the following are met:

    Jubbonti (denosumab for osteoporosis): 1) Patient at high risk of fracture; OR 2) Inadequate response/intolerance to ≥1 traditional osteoporosis treatments; OR 3) Female on aromatase inhibitor at high fracture risk using denosumab to increase bone mass; OR 4) Men at high fracture risk on androgen deprivation therapy; OR 5) Glucocorticoid‑induced osteoporosis at high risk.

    Coverage duration 2 years; prerequisite Part D drug required.

    Jynarque / tolvaptan (chunk 58)

    Initial and reauthorization criteria for ADPKD:

    Jynarque (initial): 1) Diagnosis of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD); AND 2) Either: a) Patient receiving Jynarque ≤18 months AND ALT/AST/bilirubin measured prior to initiation, at 2 and 4 weeks, then monthly for first 18 months; OR b) Patient receiving Jynarque >18 months AND ALT/AST/bilirubin measured at least every 3 months. Patient must not have a history of significant liver impairment or injury (excluding uncomplicated polycystic liver disease).

    Coverage duration 1 year; reauthorization requires documented positive clinical response and continued liver monitoring per schedule; no prerequisite Part D drug required.

    Kalydeco (ivacaftor) (chunk 59)

    Covered when ALL criteria met:

    Kalydeco coverage criteria: 1) Documented diagnosis of cystic fibrosis (CF) AND at least one CFTR mutation responsive to ivacaftor based on clinical or in vitro assay data (or FDA‑cleared mutation test when genotype unknown); 2) For granules formulation: age ≥1 month; 3) Coverage duration: 2 years.

    Kalydeco is not effective for patients homozygous for the F508del CFTR mutation; no prerequisite Part D drug required.

    Kerendia / Kesimpta (chunks 60)

    Covered when ALL of the following are met (per product):

    Kerendia: Documented diagnosis of chronic kidney disease associated with type 2 diabetes OR heart failure with LVEF ≥40%; prescriber as specified; coverage 2 years.

    No prerequisite Part D drug required.

    Kesimpta: Documented diagnosis of relapsing forms of multiple sclerosis (CIS, RRMS, active SPMS); prescriber must be neurologist; coverage 2 years.

    No prerequisite Part D drug required.

    Kineret (anakinra) (chunks 61-62)

    Indication‑specific initial and reauthorization criteria:

    Kineret — RA initial: 1) Diagnosis of moderately to severely active rheumatoid arthritis AND either a) trial and failure, contraindication, or intolerance to two of: etanercept, one formulary adalimumab product, abatacept, upadacitinib, tofacitinib OR attestation that trials are inappropriate; OR b) continuation of prior therapy.

    Prescribed by or in consultation with a rheumatologist; reauth requires documented clinical response (e.g., reduced swollen/tender joint count); coverage duration 1 year; prerequisite Part D drug required.

    Kineret — NOMID initial: 1) Diagnosis of NOMID AND confirmatory evidence via NLRP3 mutation OR two clinical features among listed PLUS elevated acute phase reactants; 2) Prescribed by allergist/immunologist, rheumatologist, or pediatrician.

    Reauth requires positive clinical response; coverage 1 year; prerequisite Part D drug required.

    Kisqali (ribociclib) (chunk 63)

    Covered when ALL criteria met:

    Kisqali coverage criteria: Documented HR‑positive, HER2‑negative advanced/metastatic breast cancer used in combination with an aromatase inhibitor as initial endocrine‑based therapy OR with fulvestrant as initial endocrine‑based therapy or after progression; OR HR‑positive, HER2‑negative stage II/III early breast cancer at high risk of recurrence when used with an aromatase inhibitor.

    Prescriber must be an oncologist; coverage 2 years; prerequisite Part D drug required.

    Komzifti (chunk 66)

    Covered when ALL criteria met:

    Komzifti coverage criteria: Documented relapsed or refractory AML with presence of susceptible NPM1 mutation; coverage 2 years; approve continuation of prior therapy; no prerequisite Part D drug required.

    Prescriber must be oncologist.

    Koselugo (selumetinib) (chunk 66)

    Covered when ALL criteria met:

    Koselugo coverage criteria: Documented neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas; age ≥1 year; prescriber neurologist or oncologist; coverage 2 years; no prerequisite Part D drug required.

    Krazati (chunk 67)

    Covered when ALL criteria met:

    Krazati — NSCLC: Locally advanced or metastatic NSCLC that is KRAS G12C‑mutated AND patient has received ≥1 prior systemic therapy.

    Prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Krazati — CRC: KRAS G12C‑mutated locally advanced or metastatic colorectal cancer AND prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy AND use in combination with cetuximab; coverage 2 years; prerequisite Part D drug required.

    Prescriber must be oncologist.

    Lapatinib ditosylate (chunk 68)

    Covered when ALL criteria met:

    Lapatinib criteria: HER2 overexpressing advanced/metastatic breast cancer AND failure of prior anthracycline and taxane AND failure of trastuzumab AND concurrent treatment with capecitabine; OR HR+ metastatic breast cancer overexpressing HER2 when used concurrently with letrozole; prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Lazcluze (amivantamab + mobocertinib context) (chunk 69)

    Covered when ALL criteria met:

    Lazcluze (amivantamab+mobocertinib context): NSCLC, locally advanced or metastatic, used as first‑line treatment in combination with amivantamab AND presence of EGFR exon 19 deletions or exon 21 L858R substitution mutations; coverage 2 years; continuation of prior therapy approved; no prerequisite Part D drug required.

    Prescriber must be oncologist.

    Lenalidomide (chunk 70)

    Covered when indication‑specific criteria are met:

    Lenalidomide indications: Previously treated follicular lymphoma in combination with rituximab; mantle cell lymphoma relapsed/progressed after ≥2 prior therapies (one including bortezomib); marginal zone lymphoma previously treated in combination with rituximab; multiple myeloma in combination with dexamethasone or as maintenance post‑autologous HSCT; transfusion‑dependent anemia due to low-/intermediate‑1‑risk MDS with 5q‑deletion; prescriber hematologist/oncologist; coverage 2 years; prerequisite Part D drug required.

    Lenvima (various doses) (chunk 68)

    Covered when indication‑specific criteria are met:

    Lenvima indications: Advanced endometrial carcinoma (pMMR) after prior systemic therapy when used with pembrolizumab; ARCC after prior antiangiogenic therapy when used with everolimus or as first‑line with pembrolizumab; unresectable HCC; locally recurrent/metastatic radioactive iodine‑refractory differentiated thyroid cancer; prescriber oncologist; coverage 2 years; prerequisite Part D drug required.

    Various dose strengths listed in product entries.

    Lidocaine patch 5% (chunk 69)

    Covered when criteria met:

    Lidocaine patch 5%: Postherpetic neuralgia or diabetic neuropathy after failure, adverse reaction, or contraindication to gabapentin OR patient not candidate for opioid or other oral pain management; new members with well‑controlled pain on patches may be authorized; coverage 2 years; prerequisite Part D drug required.

    Livtencity (maribavir) (chunk 69)

    Covered when ALL criteria met:

    Livtencity coverage criteria: Patient ≥35 kg with documented post‑transplant CMV infection/disease refractory to treatment (with or without genotypic resistance) to ganciclovir, valganciclovir, cidofovir, or foscarnet; coverage 2 years; prerequisite Part D drug required.≥35 kg

    Lonsurf (trifluridine/tipiracil) (chunk 70)

    Covered when ALL criteria met:

    Lonsurf indications: Metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and if RAS wild‑type, an anti‑EGFR therapy; OR metastatic gastric/gastroesophageal junction adenocarcinoma after ≥2 prior lines including fluoropyrimidine, platinum, taxane or irinotecan, and HER2 therapy if appropriate; prescriber oncologist; coverage 2 years; prerequisite Part D drug required.

    Lorbrena (lorlatinib) (chunk 71)

    Covered when ALL criteria met:

    Lorbrena coverage criteria: Documented metastatic NSCLC with ALK‑positive tumor; prescriber oncologist; coverage 2 years; no prerequisite Part D drug required.

    Lumakras (sotorasib) (chunk 71)

    Covered when ALL criteria met:

    Lumakras criteria: 1) KRAS G12C‑mutated locally advanced or metastatic NSCLC after ≥1 prior systemic therapy; OR 2) KRAS G12C‑mutated metastatic colorectal cancer in combination with panitumumab after prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy; prescriber oncologist; coverage 2 years; prerequisite Part D drug required.

    Lybalvi (olanzapine/samidorphan) (chunk 72)

    Covered when ALL of the following are met:

    Lybalvi coverage criteria: Documented diagnosis of schizophrenia or Bipolar I disorder; prescriber must be a psychiatrist; coverage 2 years; no prerequisite Part D drug required.

    Lynparza (olaparib) (chunk 73)

    Covered when indication‑specific criteria are met:

    Lynparza — breast cancer: Deleterious or suspected deleterious gBRCA‑mutated HER2‑negative metastatic breast cancer treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting AND if HR+, prior endocrine therapy or inability to tolerate endocrine therapy; OR high‑risk early breast cancer treated with neoadjuvant or adjuvant chemotherapy; prescriber oncologist; coverage per product entry; prerequisite Part D drug may be required for some indications.

    Other Lynparza indications (ovarian, pancreatic, prostate) have specific BRCA/HRR criteria.

    Product-specific covered criteria (representative subset)

    Covered when ALL product‑specific requirements are met as listed below (representative subset):

    Antipsychotic agents (example): Documented diagnosis of schizophrenia or Bipolar I disorder AND prescribing physician is a psychiatrist; coverage 2 years; prerequisite Part D therapy NOT required.

    Representative product‑level entry.

    Lynparza (olaparib): Indication‑specific molecular test documentation (germline/somatic BRCA or HRR depending on indication) AND prior chemotherapy/endocrine therapy as specified AND prescriber is an oncologist; coverage 2 years; some indications require prior Part D drug.

    Representative product entry.

    Lytgobi (futibatinib): Previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements AND prescribed by or in consultation with an oncologist; coverage 2 years; no prerequisite Part D therapy required.

    Representative product entry.

    Autoimmune specialty drugs (selected examples)

    Covered when ALL of the following are met (per product‑specific entries):

    Autoimmune specialty drugs — RA example: Diagnosis of moderately to severely active rheumatoid arthritis AND trial and failure, contraindication, or intolerance to one of: methotrexate, leflunomide, or sulfasalazine; prescriber specialty specified; coverage 2 years; prerequisite Part D drug required where noted.

    Representative of autoimmune biologic/small molecule entries.

    Orkambi (cystic fibrosis)

    Covered when ALL of the following are met:

    Orkambi genotype requirement: Documented diagnosis of cystic fibrosis AND homozygous for the F508del mutation; coverage 2 years.

    Prescriber specialty as specified in policy; no prerequisite Part D drug required.

    Piqray (PIK3CA-mutated breast cancer)

    Covered when ALL of the following are met:

    Piqray criteria: Documented HR‑positive, HER2‑negative, PIK3CA‑mutated advanced/metastatic breast cancer AND progressed on or after an endocrine‑based regimen AND used in combination with fulvestrant; prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Rezdiffra (MASH/NASH)

    Initial coverage when ALL of the following are met:

    Rezdiffra initial: 1) Diagnosis of metabolic dysfunction‑associated steatohepatitis (MASH) without cirrhosis; 2) Fibrosis stage F2 or F3 confirmed by specified serum and/or imaging biomarkers or liver biopsy within past 12 months; 3) Presence of ≥1 metabolic risk factor (e.g., T2DM, hypertension, obesity); prescriber gastroenterologist or hepatologist; coverage 2 years.F2‑F3

    Reauth requires positive response and no progression to cirrhosis; no prerequisite Part D drug required.

    Rezlidhia (IDH1-mutant AML)

    Covered when ALL of the following are met:

    Rezlidhia criteria: Documented relapsed or refractory AML with documentation that the cancer has a susceptible IDH1 mutation; prescriber oncologist/hematologist; coverage 2 years.

    No prerequisite Part D drug required.

    Rydapt (AML with FLT3 mutation)

    Covered when ALL of the following are met:

    Rydapt in AML: Documented AML that is FLT3 mutation‑positive AND Rydapt is being used as first‑line therapy in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation; prescriber hematologist/oncologist; coverage 2 years.

    Rydapt will not be approved as single‑agent induction therapy for AML.

    Rubraca (recurrent ovarian cancer; prostate cancer)

    Covered when ALL of the following are met:

    Rubraca — recurrent ovarian cancer (maintenance): Documented deleterious BRCA mutation (germline and/or somatic) associated with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer AND member is in complete or partial response to platinum‑based chemotherapy; prescriber oncologist; coverage 2 years; will not be approved for concurrent use with other chemotherapy agents; prerequisite Part D drug required in product context.
    Rubraca — mCRPC: Deleterious BRCA (germline/somatic)‑associated metastatic castration‑resistant prostate cancer treated with prior androgen receptor‑directed therapy and taxane chemotherapy; prescriber oncologist; coverage 2 years.

    Rydapt

    Covered when ALL of the following are met:

    Rydapt indications (expanded): FLT3 mutation‑positive AML as first‑line in combination with cytarabine and daunorubicin induction and cytarabine consolidation OR documented Mast Cell Leukemia OR aggressive systemic mastocytosis (ASM) or SM‑AHN; prescriber hematologist/oncologist or allergist; coverage 2 years; not approved as single‑agent induction for AML.

    Skyrizi (plaque psoriasis, psoriatic arthritis, IBD)

    Covered when ALL of the following are met:

    Skyrizi indications: Indication‑specific documentation for plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis; for plaque psoriasis failure or intolerance to listed topical/systemic therapies; prescriber dermatology/rheumatology/gastroenterology; coverage 2 years; prerequisite Part D drug required for some indications.

    Sodium Oxybate; Somavert

    Covered when ALL of the following are met:

    Sodium Oxybate indications: Diagnosis of narcolepsy with cataplexy or excessive daytime sleepiness OR idiopathic hypersomnia; coverage 2 years.
    Somavert for acromegaly: Documented diagnosis of acromegaly with failure of or intolerance to octreotide AND not candidate for or inadequate response to surgery/radiation; prescriber endocrinologist; coverage 2 years; prerequisite Part D drug required.

    Sorafenib

    Covered when ALL of the following are met:

    Sorafenib indications: Advanced renal cell carcinoma OR unresectable HCC OR locally recurrent/metastatic differentiated thyroid carcinoma refractory to radioactive iodine; prescriber nephrologist/oncologist/urologist; coverage 2 years.

    Stelara

    Covered when ALL of the following are met:

    Stelara indications: Documented indication (Crohn's, plaque psoriasis, psoriatic arthritis, UC) AND trial, intolerance, or contraindication to Yesintek or Steqeyma; prescriber specialty required; coverage 2 years; prerequisite Part D drug required.

    Stivarga

    Covered when ANY of the following are met:

    Stivarga indications: GIST with failure/intolerance/contraindication to imatinib and sunitinib OR HCC after prior failure of sorafenib OR metastatic colorectal cancer previously treated with specified chemotherapies/biologics; prescriber oncologist; coverage 2 years; prerequisite Part D drug required.

    Tabrecta

    Covered when ALL of the following are met:

    Tabrecta for MET exon 14 skipping NSCLC: Documented metastatic NSCLC with MET exon 14 skipping mutation; prescriber oncologist; coverage 2 years; no prerequisite Part D drug required.

    Tadalafil (BPH)

    Covered when ALL of the following are met:

    Tadalafil (BPH): Documented diagnosis or signs/symptoms of benign prostatic hyperplasia (BPH) AND documented failure, adverse reaction, or contraindication to a 30‑day trial of at least two listed BPH medications (e.g., alfuzosin, doxazosin, dutasteride, finasteride, tamsulosin, terazosin); coverage 2 years.30 days

    Tadalafil excluded for erectile dysfunction.

    Tafinlar

    Covered when ANY of the following are met (by indication):

    Tafinlar indications: Unresectable/metastatic melanoma with BRAF V600E mutation (single agent) OR combinations with trametinib for other BRAF V600E/V600K indications (NSCLC, ATC, solid tumors with BRAF V600E, low grade glioma); prescriber oncologist; coverage 2 years.

    Tagrisso

    Covered when ANY of the following are met (by indication):

    Tagrisso indications: Metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations for first‑line use OR metastatic EGFR T790M mutation‑positive NSCLC after progression OR adjuvant therapy after resection for qualifying EGFR mutations OR unresectable stage III NSCLC whose disease has not progressed after chemoradiation with qualifying EGFR mutations; prescriber oncologist; coverage 2 years; prerequisite Part D drug required.

    Talzenna

    Covered when ALL of the following are met:

    Talzenna indications: Deleterious or suspected deleterious germline BRCA‑mutated HER2‑negative locally advanced or metastatic breast cancer OR HRR gene‑mutated mCRPC when used in combination with enzalutamide; prescriber oncologist; coverage 2 years; no prerequisite Part D drug required.

    Tasimelteon

    Covered when ANY of the following are met:

    Tasimelteon indications: Smith‑Magenis Syndrome with nighttime sleep disturbances OR completely blind patients with non‑24‑hour sleep‑wake disorder; prescriber neurologist or sleep specialist; coverage 2 years; will not be authorized for insomnia.

    Tavneos

    Covered when ALL of the following are met:

    Tavneos for severe active ANCA‑associated vasculitis: 1) Diagnosis of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA); 2) Patient is receiving concurrent immunosuppressant therapy with cyclophosphamide OR rituximab; 3) Patient is concurrently on glucocorticoids OR has history of contraindication/intolerance to glucocorticoids; prescriber nephrologist/pulmonologist/rheumatologist; coverage 2 years; prerequisite Part D drug required.

    Tazverik

    Covered when ANY of the following are met (by indication):

    Tazverik indications: Metastatic or locally advanced epithelioid sarcoma not eligible for complete resection OR relapsed/refractory follicular lymphoma with EZH2 mutation after ≥2 prior systemic therapies OR relapsed/refractory follicular lymphoma with no satisfactory alternative treatment options; prescriber oncologist; coverage 2 years; prerequisite Part D drug required.

    Teriparatide

    Covered when ALL of the following are met:

    Teriparatide for osteoporosis: Postmenopausal women with osteoporosis, men with primary or hypogonadal osteoporosis, or men/women with glucocorticoid‑associated osteoporosis at high fracture risk AND inadequate response or intolerance to at least one traditional osteoporosis treatment; coverage 2 years; prerequisite Part D drug required.

    Tetrabenazine

    Covered when ALL of the following are met:

    Tetrabenazine for Huntington chorea: Documented diagnosis of chorea associated with Huntington's Disease; prescriber must be a neurologist; coverage 2 years; no prerequisite Part D drug required.

    Tibsovo

    Covered when ANY of the following are met (by indication):

    Tibsovo indications: Relapsed/refractory AML with susceptible IDH1 mutation OR new diagnosis AML with susceptible IDH1 mutation used as monotherapy or with azacitidine if ≥75 years or ineligible for intensive chemo OR locally advanced/metastatic cholangiocarcinoma previously treated OR relapsed/refractory MDS; prescriber hematologist/oncologist; coverage 2 years; prerequisite Part D drug required.

    Fentanyl Citrate Oral Transmucosal (TIRF)

    Covered when ALL of the following are met:

    TIRF — breakthrough cancer pain: 1) Management of breakthrough pain in adult cancer patients already receiving and tolerant to around‑the‑clock opioid therapy for underlying persistent cancer pain (opioid‑tolerant definition in policy); 2) Patient remains on around‑the‑clock opioids when taking fentanyl transmucosal; 3) Prescribing physician is an oncologist or pain management specialist; 4) Coverage duration: 2 years; 5) Approvable for pediatric patients 16 years and older for lozenges.

    TIRF products not covered for any non‑cancer pain indication.

    Trikafta

    Covered when ALL of the following are met:

    Trikafta initial and reauthorization: Initial: Diagnosis of cystic fibrosis with at least one responsive CFTR mutation (F508del or other responsive mutation); age/formulation limits (granules 2–<6 years; tablets ≥6 years); prescribed by or in consultation with a pulmonologist or CF care center specialist. Reauthorization: Patient demonstrates positive clinical response (e.g., improved ppFEV1 or fewer pulmonary exacerbations). Coverage duration: 2 years; prerequisite Part D drug not required.

    Transmucosal Immediate-Release Fentanyl (TIRF) - fentanyl lozenges; Trikafta - cystic fibrosis

    Covered when ALL of the following are met:

    TIRF coverage criteria (lozenges): 1) Management of breakthrough pain in adult cancer patients; 2) Patient is already receiving and tolerant to around‑the‑clock opioid therapy for persistent cancer pain (opioid‑tolerant per policy definition); 3) Prescribing physician must be an oncologist or pain management specialist; 4) Coverage duration: 2 years; 5) Approve for pediatric patients 16 years and older for fentanyl lozenges.

    TIRF products not covered for any non‑cancer pain indication.

    Trikafta — cystic fibrosis (initial): 1) Diagnosis of cystic fibrosis; 2) At least one qualifying CFTR mutation (F508del OR responsive mutation based on clinical/in vitro data); 3) Age/formulation: granules for 2 to <6 years, tablets for ≥6 years; 4) Prescribed by or in consultation with pulmonologist or CF care center specialist; 5) Coverage duration: 2 years. Reauthorization requires demonstration of positive clinical response (e.g., improved ppFEV1 or decreased pulmonary exacerbations).

    Truqap - breast cancer (PIK3CA/AKT1/PTEN-altered)

    Covered when ALL of the following are met:

    Truqap initial therapy: 1) Diagnosis of locally advanced or metastatic HR‑positive, HER2‑negative breast cancer; 2) To be taken in combination with fulvestrant; 3) Tumor has one or more PIK3CA/AKT1/PTEN alterations; 4) Progression on at least one endocrine‑based regimen in metastatic setting OR recurrence on/within 12 months of completing adjuvant therapy; 5) Coverage duration: 2 years; 6) Prerequisite Part D drug required.

    Prescriber oncologist as specified in product entry.

    Tukysa - HER2-positive breast cancer or HER2-positive RAS wild-type colorectal cancer

    Covered when ALL of the following are met:

    Tukysa indications: 1) Advanced unresectable or metastatic HER2‑positive breast cancer with prior anti‑HER2 regimens in metastatic setting AND used in combination with trastuzumab and capecitabine; OR 2) RAS wild‑type HER2‑positive unresectable or metastatic colorectal cancer progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy AND used in combination with trastuzumab; prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Turalio CAPS 125MG - tenosynovial giant cell tumor (TGCT)

    Covered when ALL of the following are met:

    Turalio (TGCT): 1) Documented symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations; 2) Condition not amenable to improvement with surgery; 3) Coverage duration: 2 years; 4) No prerequisite Part D drug required.

    Multiple indications (Ubrelvy, RA/SJIA/PJIA/SSc-ILD etc.) - biologic/small molecule criteria (example group)

    Covered when criteria per indication are met:

    Biologic/small molecule indications (example): RA initial: Diagnosis of moderately to severely active RA AND either (a) trial and failure, contraindication, or intolerance to two of: Enbrel, one formulary adalimumab product, Orencia, Rinvoq, Xeljanz OR attestation that trials are inappropriate OR (b) continuation of prior therapy; prescribed by or in consultation with rheumatologist; coverage duration 1 year; prerequisite Part D drug required. Similar TF/C/I and prescriber requirements apply for GCA, SJIA, PJIA, SSc‑ILD with indication‑specific trial durations and reauthorization requiring evidence of positive clinical response.

    Representative example entry from policy.

    Ustekinumab - multiple indications

    Covered when ALL of the following are met:

    Ustekinumab indications: Indications include Crohn's disease (moderate‑severe), plaque psoriasis (moderate‑severe after failure/intolerance to topical/systemic therapies), psoriatic arthritis, ulcerative colitis (moderate‑severe). For all indications, trial, intolerance, or contraindication to Yesintek or Steqeyma required; prescriber specialty as specified; coverage 2 years; prerequisite Part D drug required.

    Valtoco - acute seizure treatment

    Covered when ALL of the following are met:

    Valtoco criteria: Documented diagnosis of a seizure disorder requiring acute treatment; prescribing physician must be a neurologist; coverage 2 years; no prerequisite Part D drug required.

    Applies to specified Valtoco dose strengths listed in policy.

    Vanflyta - FLT3-ITD AML

    Covered when ALL of the following are met:

    Vanflyta criteria: Documented newly diagnosed AML that is FLT3‑ITD positive; prescriber oncologist/hematologist; coverage 2 years; no prerequisite Part D drug required.

    Venclexta - AML and CLL/SLL

    Covered when ALL of the following are met:

    Venclexta indications: AML: used first‑line in combination with azacitidine, decitabine, or low‑dose cytarabine AND patient is ≥75 years OR unfit for intensive induction chemotherapy; OR CLL/SLL: documented diagnosis; prescriber hematologist/oncologist; coverage 2 years; no prerequisite Part D drug required.

    Voquezna family - H. pylori, HRH, MHRH, NERD

    Covered when ALL of the following are met (indication‑specific):

    Voquezna — H. pylori/HRH/MHRH/NERD: H. pylori: diagnosis of H. pylori infection AND trial and failure/contraindication/intolerance to bismuth quadruple therapy (for Dual and Triple Pak) where required. HRH/MHRH/NERD: trial and inadequate response/contraindication/intolerance to two generic PPIs with symptom duration criteria for NERD; coverage duration varies by indication (H. pylori/NERD: 1 month; HRH: 2 months; MHRH: 6 months); prerequisite Part D drug required.

    Prescriber specialty per policy; coverage durations vary by indication.

    Voriconazole - invasive fungal infections

    Covered when ALL of the following are met:

    Voriconazole indications: Documented infection caused by Aspergillus or Candida (including candidemia, invasive candidiasis, invasive aspergillosis, CNS infection, cardiovascular infections, esophageal candidiasis, pulmonary aspergillosis, etc.) OR serious fungal infection caused by Scedosporium apiospermum or Fusarium intolerant/refractory to other therapy; coverage 2 years; no prerequisite Part D drug required.

    Vosevi - hepatitis C

    Covered when applied consistent with clinical guidance:

    Vosevi criteria: Criteria applied consistent with current AASLD‑IDSA guidance; prescriber must be gastroenterologist, hepatologist, or infectious disease specialist; coverage duration consistent with guidance; no prerequisite Part D drug required.

    Vyndamax - ATTR-CM

    Covered when ALL of the following are met:

    Vyndamax — ATTR‑CM: 1) Diagnosis of transthyretin‑mediated amyloidosis with cardiomyopathy (ATTR‑CM); AND one of: a) presence of a transthyretin (TTR) mutation (e.g., V122I), b) cardiac or noncardiac tissue biopsy with histologic confirmation of TTR amyloid deposits, OR c) cardiac MRI or scintigraphy suggestive of amyloidosis AND absence of light‑chain amyloidosis; 2) Documentation patient has NYHA Functional Class I, II, or III heart failure; 3) Prescribed by a cardiologist; coverage duration: plan year; reauth requires continued NYHA I‑III.NYHA I‑III

    No prerequisite Part D drug required.

    Welireg - von Hippel-Lindau disease / RCC / PPGL

    Covered when ALL of the following are met:

    Welireg indications: 1) von Hippel‑Lindau disease requiring therapy for associated RCC, CNS hemangioblastomas, or pancreatic NETs not requiring immediate surgery; OR 2) Advanced RCC following PD‑1/PD‑L1 inhibitor and a VEGF‑TKI; OR 3) Locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL); prescriber oncologist; coverage 2 years; prerequisite Part D drug required.

    Welireg (ATTR-CM) initial and reauthorization

    Covered when ALL of the following are met (initial and reauthorization):

    Welireg (ATTR‑CM) initial/reauthorization: 1) Diagnosis of transthyretin‑mediated amyloidosis with cardiomyopathy (ATTR‑CM); 2) Confirmatory evidence: one of: a) presence of TTR mutation, b) cardiac/noncardiac tissue biopsy with histologic confirmation of TTR amyloid deposits, OR c) cardiac MRI or scintigraphy suggestive of amyloidosis AND absence of light‑chain amyloidosis; 3) Documentation of NYHA Functional Class I, II, or III; 4) Prescribed by a cardiologist; coverage duration: plan year; reauth requires continued NYHA I‑III.NYHA I‑III

    Wyost (oncology indications)

    Covered when ANY of the following indications are met with required documentation:

    Wyost — oncology indications: Indications include: von Hippel‑Lindau disease requiring therapy for associated RCC/CNS hemangioblastomas/pancreatic NETs; advanced RCC after PD‑1/PD‑L1 inhibitor and VEGF‑TKI; or locally advanced/unresectable/metastatic PPGL; prescriber oncologist; coverage 2 years; prerequisite Part D drug required where noted.

    Representative grouping of Wyost oncology entries.

    Wyost (denosumab) specific indications

    Covered when ANY of the following are met:

    Wyost (denosumab) indications: 1) Prevention of skeletal‑related events in patients with multiple myeloma or bone metastases from solid tumors; 2) Treatment of unresectable giant cell tumor of bone (GCTB) or where surgery likely results in severe morbidity; 3) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy; coverage 2 years.

    Xalkori (crizotinib) indications

    Covered when ANY of the following documented diagnoses are present:

    Xalkori indications: 1) Metastatic NSCLC that is ALK‑positive OR ROS1‑positive; 2) Relapsed/refractory systemic ALCL that is ALK‑positive; 3) Unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK‑positive; prescriber must be oncologist; coverage 2 years.

    Xolair (omalizumab) indications

    Covered when ALL of the following apply (by indication‑specific branches):

    Xolair — Asthma: 1) Moderate‑ to‑severe persistent asthma with failure of treatment regimen including two or more of inhaled corticosteroids, oral corticosteroids, leukotriene modifiers, inhaled long‑acting bronchodilators OR inability to tolerate these; 2) Definitive sensitivity on allergy testing to perennial allergens; 3) Pre‑treatment serum IgE between 30 and 1,300 IU/mL; prescriber specialties specified; coverage 2 years.IgE 30‑1300 IU/mL

    Other Xolair branches include CSU and nasal polyps per indication.

    Tofacitinib and related agents (implied)

    Covered when indicated disease criteria and prior therapy requirements are met:

    Tofacitinib and related agents — autoimmune indications: Conditions such as ankylosing spondylitis, RA, PJIA, psoriatic arthritis, ulcerative colitis require diagnosis of active disease and prior inadequate response/intolerance to specified conventional therapies and often prior TNF inhibitor failure as detailed per indication; prescriber must be or consult with relevant specialist; coverage 2 years; prerequisite Part D drug required in some cases.

    Representative of implied entries in policy.

    Zejula (niraparib) ovarian cancer

    Covered when ONE of the following is met:

    Zejula — maintenance therapy after platinum response: Advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum‑based chemotherapy.

    OR

    Zejula — BRCA‑mutant recurrent disease: Recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer with deleterious or suspected deleterious germline BRCA mutation in complete or partial response to platinum‑based chemotherapy; prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    Zelboraf (vemurafenib)

    Covered when the following apply:

    Zelboraf indications: Erdheim‑Chester Disease with BRAF V600 mutation OR unresectable/metastatic melanoma that is BRAF V600E mutation‑positive; prescriber oncologist/hematologist; coverage 2 years.

    Zelboraf not indicated for wild‑type BRAF melanoma.

    Ztalmy (seizures in CDKL5 deficiency disorder)

    Covered when the following apply:

    Ztalmy — CDKL5 deficiency disorder: Documented diagnosis of seizures associated with CDKL5 deficiency disorder (CDD); prescriber neurologist or consult; coverage 2 years.

    Zydelig (idelalisib) for CLL

    Covered when the following apply:

    Zydelig for CLL: Documented relapsed CLL and use of Zydelig (idelalisib) in combination with rituximab; prescriber hematologist/oncologist; coverage 2 years.

    Initial Therapy Requirements

    Continuation / Reauthorization Criteria

    Prior Authorization, Documentation & Denial Risks

    Prior Authorization

    Abilify Mycite — prior authorization and psychiatrist prescriber required

    Prior authorization is required. Submit documentation showing a diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia and evidence of worsening symptoms with oral aripiprazole; the prescriber must be a psychiatrist. Approval duration: 2 years.

    Prior Authorization

    Arikayce — prior authorization and specialist consult required

    Prior authorization is required. Provide documentation of MAC lung disease, use as part of a combination antibacterial regimen, and failure to achieve at least two negative sputum cultures after ≥6 consecutive months of a multidrug background regimen; prescription must be by or in consultation with an infectious disease specialist or pulmonologist. Approval duration: 2 years.

    Prior Authorization

    Prior authorization required for listed specialty drugs

    Step Therapy & Prior Treatment Requirements

    Step requirementDetails
    Trial and failure or contraindication/intolerance to one conventional therapy prior to biologic (adalimumab) useRequired for indications including rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, PJIA, and others as specified; conventional therapies include methotrexate, leflunomide, or sulfasalazine (RA/PJIA) or listed topical/systemic therapies for dermatologic indications
    Documentation oftrial/failure or documented contraindication/intolerance must be provided with prior authorization requestPrescriber restriction: prescribed by or in consultation with appropriate specialist (dermatologist, rheumatologist, gastroenterologist, or ophthalmologist) as indicated; coverage duration typically 2 years
    Step requirementListed therapies to try before biologic
    Try listed non-biologic/topical or conventional therapies prior to biologicFor plaque psoriasis: trial and failure or intolerance to at least one topical therapy class (corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, coal tar)
    For non-radiographic axial spondyloarthritis and enthesitis-related arthritis: trial and failure, contraindication, or intolerance to two NSAIDs at maximally indicated doses for at least one monthPrescriber restrictions: specialist consultation (eg, dermatologist, rheumatologist) and documentation required
    Step requirementTopical therapies (examples) / Duration
    Prior topical therapy trial required before biologic for dermatologic indicationsExamples: medium or higher potency topical corticosteroids, pimecrolimus, tacrolimus, crisaborole; trial/failure of minimum 30-day supply (14 days allowed for topical corticosteroids in sensitive areas)
    Documentation: supply/duration and reason for failure/intolerance or contraindication must be submitted with prior authorizationCoverage duration and prescriber specialty as per product entry (commonly 2 years)
    Step requirementExamples of required prior trials/failures
    Prior trials or failures required where specified per product entryEverolimus (Advanced HR+ BC): failure of letrozole or anastrozole; Fotivda (ARCC): prior systemic therapies; Fruzaqla: prior fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy and anti-VEGF therapy
    Jakafi/Jaypirca: prior systemic therapy failure required for chronic GVHD and other hematologic indications; prescriber must be specialist (oncologist/hematologist)Prerequisite Part D drug may be required for selected agents — document prior therapies as listed
    Step requirementKineret (RA) prior trials
    Required prior trials for RA indication of Kineret unless attestation that trials are inappropriateMember must have trial and failure, contraindication, or intolerance to TWO of: etanercept, one formulary adalimumab product, abatacept, upadacitinib, or tofacitinib; OR attestation that trials are inappropriate; prescriber: rheumatologist
    Reauthorization: documented clinical response required (eg, reduced swollen/tender joint count or symptomatic improvement); coverage duration: 1 yearPrerequisite Part D drug required as noted in product entry
    Step requirementPrerequisite Part D drug indicator / when applies
    Indicator whether product DOES or DOES NOT require a prerequisite Part D drugMany products specify 'Criteria DOES require use of a prerequisite Part D drug' (examples: Lynparza in some indications, Nexletol, Everolimus entries); others explicitly state DOES NOT require (eg, Orgovyx, some agents)
    When 'DOES require' applies: prior documented use of the specified Part D agent(s) must be submitted for authorization (see product-specific entry)When 'DOES NOT require' applies: no prerequisite Part D therapy needed (documentation still required per product criteria)
    Step requirementPrerequisite conventional therapy or prior biologic examples
    Prerequisite conventional therapy or prior biologic (e.g., TNF inhibitors) required for many rheumatologic and GI indicationsExamples: RA/PJIA require trial and failure to methotrexate, leflunomide, or sulfasalazine; some UC/CD or ankylosing spondylitis entries require inadequate response or intolerance to one or more TNF inhibitors (eg, Enbrel, Humira)
    Stelara/Ustekinumab examples: trial, intolerance, or contraindication to Yesintek or Steqeyma prior to coverage (Stelara notes) and prescriber specialty requirementsDocumentation of prior biologic use and reason for discontinuation must be provided
    Step requirementStelara prior trial details
    Required prior trial/intolerance/contraindication before StelaraMember must have trial, intolerance, or contraindication to Yesintek or Steqeyma prior to coverage; prescribed by or in consultation with appropriate specialist; coverage duration typically 2 years
    Document trials/failures and prescriber specialty with PA requestIf prior therapy trials are inappropriate, document rationale per product rules
    Step requirementSkyrizi prior therapy for plaque psoriasis
    Required prior therapy before Skyrizi for plaque psoriasisFor plaque psoriasis: patient must have failed or been unable to tolerate at least one topical or listed systemic therapy (examples: topical corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors); prescriber: dermatologist; coverage duration typically 2 years
    Document duration and reason for failure/intolerance (minimums as specified per topical/systemic class) when submitting PAReauthorization requires evidence of clinical benefit as described in product entry
    Step requirementRequired prior to approval for certain rheumatologic/autoimmune indications
    Required prior to approval for specified rheumatologic/autoimmune indicationsMany indications require trial and failure, contraindication, or intolerance to specified conventional therapies and often prior TNF inhibitor failure where noted (eg, RA, ankylosing spondylitis, UC, CD)
    Prescriber specialty restrictions apply (rheumatologist, gastroenterologist, dermatologist) and documentation of trials/failures must be submittedCoverage durations and prerequisite Part D drug status vary by product entry
    Step requirementVoquezna prerequisite therapy requirements
    Required prior to approval for Voquezna indicationsH. pylori: trial and failure, contraindication, or intolerance to bismuth quadruple therapy required; HRH/MHRH/NERD: trial and inadequate response or intolerance to two generic PPIs required with symptom-duration criteria for NERD
    Document prior PPI or bismuth quadruple therapy trials and reason for failure/intolerance with PA submissionCoverage durations by indication specified in product entry (eg, H. pylori/NERD 1 month; HRH 2 months; MHRH 6 months)
    Step requirementDocument trials/failures of listed therapies prior to authorization
    Document trials/failures of listed therapies prior to authorizationFor all products with step therapy requirements, prior authorization must include documentation of trials, durations, and reasons for discontinuation or intolerance for listed conventional, topical, or Part D prerequisite agents
    Failure to provide required documentation may result in denial or delay; submit prescriber specialty and clinical evidence per product-specific criteriaWhen trials are inappropriate, include attestation and supporting rationale per policy guidance

    Billing Codes, Definitions & Key Values

    Product-level (no billing codes provided)mixed
    none listedNo explicit CPT/HCPCS/ICD-10 codes provided in this excerpt; product-level clinical criteria only.
    Opioid tolerance definition — TIRF requirement
    Opioid-tolerant definitionAdults must be receiving around‑the‑clock opioid therapy equivalent to morphine 60 mg oral daily, fentanyl transdermal 25 mcg/hour, oxycodone 30 mg oral daily, hydromorphone 8 mg oral daily, or an equianalgesic opioid dose daily for a week or longer
    Indication scopeApplies to Transmucosal Immediate‑Release Fentanyl (TIRF) products used for breakthrough cancer pain (fentanyl lozenges referenced)
    Required concomitant therapyPatient must remain on around‑the‑clock opioid therapy while using fentanyl transmucosal
    Age noteApprovable for pediatric patients 16 years of age and older for fentanyl lozenges
    Prescriber restrictionPrescribing physician must be an oncologist or a pain management specialist

    Coverage Determination by Setting (Part B vs Part D)

    Billing Rule

    Submit site-of-care details to determine Part B vs Part D

    Submit information describing the clinical use and the site/setting of the drug (infusion center, office, hospital outpatient, or home) so the plan can determine whether coverage applies under Medicare Part B or Part D.

    • State intended site of administration and clinical indication on submissions
    Billing Rule

    Site/setting of administration affects Part B vs Part D coverage

    Coverage under Medicare Part B or Part D depends on the clinical use and the site/setting of administration; submit setting information (infusion center, hospital outpatient, office, or home) with the request to ensure correct benefit determination.

    Policy Background and Scope

    This section of the formulary lists Part D and specialty drugs included in Part 1 of the payer's 2026 prior authorization and medical necessity guidelines and summarizes the clinical conditions, prescriber expectations, prerequisite therapy and documentation typically required to support coverage decisions. It applies to multiple drug classes including oncology, hematology, biologics, neurologic and rare disease therapies and includes both initial and reauthorization criteria.

    Requests for coverage generally require submission of the documented diagnosis and any product-specific supporting information (for example: molecular or genotype test results, prior treatment history, or monitoring laboratory values). Many agents are limited to specified specialists (e.g., oncologist, hematologist, cardiologist, pulmonologist, psychiatrist) and will request evidence that the prescriber is the appropriate specialist or consulted with one.

    Prior authorization is required for most listed specialty Part D drugs; many product entries also require documentation of failure, contraindication, or intolerance to specified conventional therapies or prerequisite Part D drugs before approval. Typical approved coverage durations for products in this part are 2 years (some entries specify shorter durations, e.g., 1 year for selected agents).

    Certain products have explicit exclusions or not‑medically‑necessary statements (for example, exclusion of Transmucosal Immediate‑Release Fentanyl [TIRF] for non‑cancer pain and restriction of modafinil/armodafinil for unsupported indications such as generalized fatigue). Requests that lack required medical information or setting-of-use details may be denied or require clarification (coverage determination sometimes hinges on whether the drug use is covered under Medicare Part B versus Part D).

    Providers should submit the product-specific required medical information described in each drug entry (diagnosis, prior therapy history, specialty prescriber documentation, monitoring plans where applicable) so that the payer can determine medical necessity and the correct benefit classification.

    Key Definitions and Diagnostic Terms

    FGFR3 alterations — Balversa
    FGFR3 alteration definitionSusceptible FGFR3 genetic alterations documented in tumor (as required for Balversa use in locally advanced or metastatic urothelial carcinoma)
    Required clinical contextMember must have progressed during or following at least one line of prior systemic therapy
    Prescriber restrictionPrescribing physician must be an oncologist or urologist
    MAC lung disease — Arikayce
    MAC lung disease definitionDiagnosis of Mycobacterium avium complex (MAC) lung disease requiring use as part of a combination antibacterial regimen
    Treatment failure criterionPatient did not achieve at least two negative sputum cultures after ≥6 consecutive months of a multidrug background regimen
    Policy Summary
    Payerharvard pilgrim health care
    PolicyTufts Health One Care (HMO D‑SNP) 2026 Prior Authorization Medical Necessity Guidelines — Part 1
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the documented diagnosis and required prior therapy history and prescriber specialty as specified for the requested product.
    SourceLink
    On This Page
    Product-specific Coverage CriteriaInitial Therapy RequirementsContinuation / Reauthorization CriteriaPrior Authorization, Documentation & Denial RisksStep Therapy & Prior Treatment RequirementsBilling Codes, Definitions & Key ValuesCoverage Determination by Setting (Part B vs Part D)Policy Background and ScopeKey Definitions and Diagnostic Terms

    Coverage 2 years; prerequisite Part D drug required.

    Nexletol / Nexlizet: Elevated LDL‑C while on maximally tolerated statin therapy OR statin intolerance AND documented diagnosis of HeFH OR atherosclerotic CVD OR high CVD risk; prescriber cardiologist/endocrinologist/lipidologist; coverage 2 years; prerequisite Part D drug required.

    Representative product entry.

    Opipza: Documented diagnosis of schizophrenia OR major depressive disorder as adjunctive therapy OR irritability associated with autistic disorder in pediatric patients OR Tourette's disorder in pediatric patients AND prescribing physician is a psychiatrist or neurologist; coverage 2 years; continuation of prior therapy approved; prerequisite Part D NOT required.

    Representative product entry.

    Prior authorization is required for many listed Part D specialty drugs; submit the documented diagnosis and any required prior therapy history per the product-specific criteria. Coverage durations are specified per product entry (frequently 2 years).

    Prior Authorization

    Prior authorization: document diagnosis and prior therapy failure

    Prior authorization generally requires submission of a documented diagnosis and evidence of prerequisite therapy failure as specified for the product (for example, everolimus requires documented failure of letrozole or anastrozole).

    • Include prior therapy trial/failure dates and outcomes where required
    Prior Authorization

    Prior authorization required — product-specific documentation needed

    Prior authorization is required for many specialty products in this segment; include the indicated diagnosis, prescriber specialty when specified, and documentation of prior therapy status per the product-specific criteria.

    Documentation Required

    Jynarque (tolvaptan) PA — mandatory liver test schedule

    Prior authorization requires liver monitoring per the schedule: measure ALT, AST, and bilirubin prior to initiation, at 2 and 4 weeks after initiation, then monthly for the first 18 months if receiving Jynarque ≤18 months; if >18 months, measure at least every 3 months. Document diagnosis of rapidly progressing ADPKD and absence of significant liver impairment.

    • Pre-initiation and 2- and 4-week labs, then monthly x18 months (if ≤18 months)
    • If on therapy >18 months, labs at least every 3 months
    • Confirm no history of significant liver impairment/injury
    Prior Authorization

    Psychiatric agents — psychiatrist prescriber and documented diagnosis required

    Prior authorization is required for listed psychiatric agents. Provide a documented diagnosis of schizophrenia or Bipolar I disorder and ensure the prescriber is a psychiatrist. Approval duration: 2 years.

    Prior Authorization

    Lynparza — mutation testing and prior therapy documentation required

    Lynparza prior authorization requires documentation of the relevant mutation status (deleterious or suspected deleterious germline/somatic BRCA or HRR as applicable) and prior chemotherapy or endocrine therapy as specified by indication; prescriber must be an oncologist. Coverage duration: 2 years.

    • Include molecular test reports demonstrating BRCA/HRR mutation status
    • Document prior chemotherapy and/or endocrine therapy per indication
    Prior Authorization

    Lytgobi — FGFR2 fusion/rearrangement and prior treatment documentation required

    Prior authorization for Lytgobi requires documentation that the tumor is unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements, and documentation of prior treatment status; prescribe by or in consultation with an oncologist.

    • Submit FGFR2 fusion/rearrangement test results
    • Document prior lines of therapy and disease status
    Prior Authorization

    Prior authorization — document prior trials and outcomes

    Prior authorization for many specialty products requires documentation of the diagnosis and trials of specified conventional therapies; include prior trial details and outcomes per the product entry.

    • Document names, doses, durations, and reasons for discontinuation of prior therapies
    Prior Authorization

    Rubraca — BRCA and platinum-response documentation; prerequisite Part D noted

    Rubraca prior authorization requires documentation of a deleterious BRCA mutation (germline and/or somatic) and response to platinum-based chemotherapy for recurrent ovarian cancer; the product entry indicates a prerequisite Part D drug is required in context.

    • Submit BRCA test report and platinum-response documentation
    • Note prerequisite Part D drug relationship as indicated
    Prior Authorization

    Rydapt — FLT3 mutation confirmation and combination use required

    Rydapt prior authorization requires documented FLT3 mutation-positive AML and that Rydapt will be used as first-line therapy in combination with cytarabine and daunorubicin induction and cytarabine consolidation; the criteria indicate Rydapt does not require a prerequisite Part D drug.

    Prior Authorization

    Trikafta — PA required; no prerequisite Part D drug

    Trikafta prior authorization is required for cystic fibrosis: submit documentation of CF diagnosis and at least one responsive CFTR mutation; the policy states Trikafta does not require prior Part D drug use.

    • Include CFTR genotype showing F508del or other responsive mutation
    Prior Authorization

    TIRF — PA required for breakthrough cancer pain; opioid-tolerant adults only

    TIRF (fentanyl lozenges) prior authorization is required for management of breakthrough cancer pain in adult cancer patients who are opioid-tolerant and already receiving around-the-clock opioid therapy; prescriber must be an oncologist or pain management specialist. TIRF products are not covered for non-cancer pain.

    • Document opioid-tolerant status (e.g., morphine 60 mg/day or fentanyl transdermal 25 mcg/hr equivalent)
    • Confirm ongoing around-the-clock opioid regimen when using TIRF
    Prior Authorization

    Trikafta — age/formulation restrictions and CFTR mutation documentation required

    Trikafta prior authorization requires CF diagnosis with at least one qualifying CFTR mutation and includes age- and formulation-specific restrictions (granules for 2 to <6 years; tablets for ≥6 years); prescriber should be a pulmonologist or CF specialist. Approval duration: 2 years.

    • Specify formulation requested and patient age
    • Provide evidence of positive clinical response on reauthorization
    Step Therapy

    Voquezna — prerequisite therapy (bismuth quadruple or two PPIs) required for PA

    Voquezna prior authorization is required for indicated pack types; for H. pylori, document trial and failure (or contraindication/intolerance) to bismuth quadruple therapy; for HRH/MHRH/NERD document trial and inadequate response/intolerance to two generic PPIs as specified.

    • For H. pylori: document prior bismuth quadruple therapy trial and outcome
    • For HRH/MHRH/NERD: document trials of two generic PPIs and inadequate response
    Documentation Required

    Part D specialty drugs — submit product-specific medical information and prescriber specialty

    Prior authorization for listed Part D specialty drugs requires submission of product-specific required medical information and, when specified, the prescriber specialty; many of these products have coverage durations frequently set to 2 years.

    • Include all product-specified supporting evidence (e.g., labs, imaging, mutation tests)
    Note

    Product-specific PA requirements — follow section cross-references

    Many products in this policy are indexed; coverage and any prior authorization requirements depend on the product-specific section elsewhere in the full policy—check the index and submit the information requested for that product.

    • Refer to the policy index for product-specific PA instructions
    Step Therapy

    Dermatologic step therapy — prerequisite topical/systemic therapy required

    For dermatologic indications (e.g., plaque psoriasis) requiring biologics, prior authorization commonly requires documented trial and failure, contraindication, or intolerance to specified topical therapies (corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, or coal tar) before biologic approval.

    • Document duration and outcome of topical/systemic therapy trials as specified
    Step Therapy

    Step therapy examples — document failures or intolerances to listed prior therapies

    Some products require documented failure or intolerance to specific prior therapies (e.g., Cosentyx requires failure/intolerance to listed topical therapies for plaque psoriasis or two NSAIDs for nr-axSpA). Include trial durations where specified.

    • For nr-axSpA and ERA: document two NSAID trials at maximally indicated doses for at least one month
    Step Therapy

    Prerequisite therapy — document prior systemic therapy trials/failures

    Several products require prior trials or failures of specified therapies before approval (examples: everolimus requires failure of letrozole/anastrozole; Fotivda requires prior systemic therapies; Jakafi for chronic GVHD requires failure of one or two systemic therapies). Provide prior treatment details.

    • List prior agents, durations, and reasons for discontinuation
    Step Therapy

    Kineret (RA) — trial/failure of two alternatives required unless inappropriate

    For Kineret in rheumatoid arthritis (initial), document trial and failure, contraindication, or intolerance to two specified alternatives (e.g., etanercept, a formulary adalimumab product, abatacept, upadacitinib, tofacitinib) unless attestation that trials are inappropriate; prescriber should be or consult with a rheumatologist.

    • Provide attestation if trials are inappropriate instead of completed trials
    Documentation Required

    Prerequisite Part D therapy — confirm and document per product

    Some products explicitly require prior or prerequisite Part D drug(s); other products explicitly do not. Confirm per product entry whether a prerequisite Part D therapy is required and document use when indicated.

    • When a product 'DOES require' a prerequisite Part D drug, submit documentation of that prior Part D therapy
    Step Therapy

    Prerequisite conventional therapy trials for autoimmune agents

    Many autoimmune and rheumatologic agents require trials of conventional therapies (e.g., methotrexate, leflunomide, sulfasalazine) with documentation of trial and failure, intolerance, or contraindication prior to biologic or small-molecule therapy authorization.

    • Include documentation of conventional therapy trials and outcomes
    Documentation Required

    Genotype documentation required (Orkambi example)

    For Orkambi and similar CF drugs, provide genotype documentation; Orkambi requires documentation that the member is homozygous for the F508del mutation.

    • Attach genetic test reports confirming F508del homozygosity
    Step Therapy

    Stelara — prior trial of Yesintek or Steqeyma required

    For Stelara, document trial, intolerance, or contraindication to Yesintek or Steqeyma prior to approval; prescriber specialty is required for initial requests.

    Step Therapy

    Skyrizi — prior topical/systemic therapy failure required for plaque psoriasis

    Skyrizi prior authorization for plaque psoriasis requires documentation that the patient failed or was unable to tolerate at least one listed topical or systemic therapy prior to approval; include prior therapy details.

    Step Therapy

    Biologic/small molecule step therapy — document trials/failures to listed agents

    For many rheumatologic and pediatric autoimmune indications (RA, SJIA, PJIA), biologic or disease-modifying agents require documented trials and failures, contraindications, or intolerances to specified agents (e.g., Enbrel, adalimumab, Orencia, Rinvoq, Xeljanz) before approval.

    • Document each prior agent tried, dose, duration, and reason for discontinuation
    Note
    Documentation Required

    Abilify Mycite — submit diagnosis and oral aripiprazole worsening

    For Abilify Mycite, include documented diagnosis (bipolar I disorder, major depressive disorder, or schizophrenia) and documentation that symptoms worsened with oral aripiprazole; the prescriber must be a psychiatrist. Approval duration: 2 years.

    Documentation Required

    Balversa — FGFR3 alteration and prior progression documentation required

    For Balversa, submit documentation of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, prior progression after at least one systemic therapy, and prior PD‑1/PD‑L1 inhibitor therapy or ineligibility for such therapy; prescriber must be an oncologist.

    • Attach FGFR3 molecular testing and prior therapy history
    Documentation Required

    Document diagnosis — include diagnostic evidence per product

    A documented diagnosis is required for each product/indication listed; include clear diagnostic evidence in the submission (e.g., pathology, imaging, genetic test results) as specified by the product entry.

    • Ensure documentation aligns with the product-specific required medical information
    Documentation Required

    Dupixent — prior topical therapy trials and phenotype details required

    For Dupixent, provide documentation of prior topical therapy trials for atopic dermatitis (minimum 30-day supply, or 14 days for topical corticosteroids in sensitive areas) or other phenotype-specific clinical details for asthma, COPD, or listed eosinophilic/immune conditions; prescriber specialty should be included.

    • Specify duration and outcomes of topical therapy trials
    Documentation Required

    Everolimus (TBSO) — document postmenopausal status, exemestane use, and prior AI failure

    For everolimus (TBSO) in advanced HR+ breast cancer, submit documentation that the member is postmenopausal, is taking exemestane concurrently, and has documented failure of letrozole or anastrozole; include diagnosis and prior therapy details.

    Documentation Required

    TSC-related products — document TSC-associated diagnosis and surgical ineligibility

    For products in chunk 37 (e.g., for TSC-related indications), document the diagnosis of partial-onset seizures associated with TSC or SEGA associated with TSC and that the patient is not a candidate for surgical resection when indicated; prescriber should be a neurologist or oncologist.

    Documentation Required

    Icatibant — confirmatory lab testing required for HAE Types 1 & 2

    For Icatibant for HAE Types 1 & 2, confirm the diagnosis with laboratory testing (e.g., low C4, reduced C1 esterase inhibitor level or function) and document a history of at least one severe attack in the past six months.

    • Attach C4 and C1 esterase inhibitor level/function test results
    Documentation Required

    Tolvaptan (Jynarque) — liver monitoring schedule required

    Measure ALT, AST, and bilirubin per the Jynarque monitoring schedule: prior to initiation, at 2 and 4 weeks after initiation, then monthly for the first 18 months (if receiving ≤18 months); if >18 months on therapy, measure at least every 3 months. Document absence of significant liver impairment.

    Documentation Required

    NOMID — mutation or clinical+lab confirmation required for Kineret

    For NOMID initial approval with Kineret, provide confirmatory evidence via NLRP3 mutation testing OR documentation of two clinical features plus elevated acute phase reactants as specified.

    • Submit genetic test results or clinical feature documentation with CRP/ESR values
    Documentation Required

    Psychiatric drug documentation — diagnosis and psychiatrist prescriber required

    For listed psychiatric drugs, include a documented diagnosis of schizophrenia or Bipolar I disorder and ensure the prescribing physician is a psychiatrist.

    Documentation Required

    Lytgobi documentation — FGFR2 fusion/rearrangement and disease status required

    For Lytgobi, document unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements and that the drug is prescribed by or in consultation with an oncologist.

    • Attach FGFR2 fusion/rearrangement molecular test report
    Documentation Required

    LDL-C lowering agents — document LDL-C and statin tolerance/intolerance

    For LDL-C lowering agents (Nexletol/Nexlizet), submit documentation of elevated LDL-C on maximally tolerated statin therapy or statin intolerance, plus diagnosis of heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease, or high cardiovascular risk as specified.

    Documentation Required

    Autoimmune indications — document diagnosis and conventional therapy trial/failure

    For selected autoimmune indications (e.g., rheumatoid arthritis), document diagnosis of moderately to severely active disease and trial and failure, contraindication, or intolerance to specified conventional therapies (methotrexate, leflunomide, sulfasalazine) as required.

    Documentation Required

    Orkambi — homozygous F508del genotype documentation required

    For Orkambi, attach genotype documentation showing the member is homozygous for the F508del CFTR mutation as required.

    Documentation Required

    Piqray — PIK3CA mutation and progression on endocrine therapy required

    For Piqray, submit documentation of HR-positive, HER2-negative, PIK3CA-mutated advanced/metastatic breast cancer, evidence of progression on or after an endocrine regimen, and planned use with fulvestrant.

    Documentation Required

    Rezdiffra — fibrosis staging and metabolic risk documentation required

    For Rezdiffra (MASH/NASH), document diagnosis without cirrhosis, fibrosis stage F2 or F3 confirmed by specified biomarker/imaging or liver biopsy within the past 12 months, and presence of at least one metabolic risk factor.

    Documentation Required

    Rubraca — deleterious BRCA and platinum-response documentation required

    Rubraca prior authorization requires documentation of a deleterious BRCA mutation (germline and/or somatic) and evidence of response to platinum-based chemotherapy for recurrent ovarian cancer; prescriber must be an oncologist.

    Documentation Required

    Rydapt — FLT3 mutation and combination induction/consolidation documentation required

    Rydapt prior authorization requires documented FLT3 mutation-positive AML and use as first-line therapy in combination with cytarabine and daunorubicin induction and cytarabine consolidation, or documentation of specified mast cell diagnoses where applicable.

    Documentation Required

    Trikafta — CF diagnosis, responsive CFTR mutation, age/formulation, and specialist prescriber required

    Trikafta requires documentation of CF diagnosis and a CFTR mutation responsive to therapy; include age- and formulation-specific information and specialist prescriber or consultation. Reauthorization requires demonstration of positive clinical response.

    • Provide PPFEV1 or exacerbation data for reauthorization
    Documentation Required

    TIRF documentation — opioid tolerance and cancer breakthrough pain required

    For TIRF (fentanyl lozenges), document that the patient is an adult cancer patient with breakthrough pain who is already receiving and tolerant to around-the-clock opioid therapy (opioid-tolerant examples provided) and that the patient will remain on around-the-clock opioids when using TIRF.

    • Document opioid-tolerant regimen and equivalent dosing (e.g., morphine 60 mg/day)
    Documentation Required

    Trikafta — CF diagnosis and qualifying CFTR mutation required

    Trikafta (CF) requires documentation of CF diagnosis and at least one qualifying CFTR mutation (F508del or other responsive mutation); provide age-appropriate formulation information and specialist prescriber details.

    Documentation Required

    Venclexta (AML) — first-line combination use and patient fitness documentation required

    Venclexta for AML requires documentation that the drug is used first-line in combination with azacitidine, decitabine, or low-dose cytarabine and that the patient is ≥75 years or unfit for intensive induction chemotherapy.

    Documentation Required

    Required clinical documentation — include product-specific supporting evidence

    Provide documented diagnosis and supporting evidence as specified per product (examples: ATTR-CM requires TTR mutation or biopsy or imaging plus absence of light-chain amyloidosis and NYHA Class I–III; metastatic biomarker-positive tumors require molecular test reports).

    • Attach biopsy, imaging, or genetic testing as required by the product
    Billing Rule

    Submit site-of-care details to determine Part B vs Part D coverage

    Submit information describing the use and the setting of the drug (infusion center, office, hospital outpatient, or home) to determine whether the drug is covered under Medicare Part B or Part D; failure to submit this information may prevent correct benefit determination.

    • Specify site of care and reason for administration when submitting requests
    Denial Risk

    Documentation-linked denials — include all required evidence to avoid denial

    Requests lacking required medical information (e.g., missing diagnostic confirmation, mutation test, biopsy, or required prior therapy documentation) may be denied; ensure all product-specified supporting evidence is included.

    • Include tests, imaging, and prior therapy documentation per product criteria
    Denial Risk

    Copiktra — document diagnosis and ≥2 prior therapies to avoid denial

    Copiktra requires a documented diagnosis of relapsed or refractory CLL/SLL and at least two prior therapies; absence of these documented prior therapies would trigger denial.

    Documentation Required

    CLL/MCL — document diagnosis and prior therapy/transplant status

    For many hematology indications (e.g., CLL, MCL), document the diagnosis and, when applicable, prior therapies or transplant ineligibility; lack of these will risk denial.

    Denial Risk

    Icatibant exclusion — do not submit for acquired angioedema or concurrent ACE inhibitor use

    Icatibant will not be approved for members with acquired angioedema or those concurrently taking an ACE inhibitor; ensure exclusion criteria are considered before submission.

    Denial Risk

    Iclusig exclusion — not for newly diagnosed chronic phase CML

    Iclusig will not be approved for members with newly diagnosed chronic phase CML; ensure the patient meets the product's approved disease-stage criteria before requesting authorization.

    Denial Risk

    Kalydeco genotype exclusion — F508del homozygous patients not eligible

    Kalydeco is not effective for patients homozygous for the F508del CFTR mutation; therapy would be denied for that genotype—verify genotype prior to submission.

    Denial Risk

    Lynparza — missing mutation or prior therapy documentation may trigger denial

    Lynparza approvals depend on documented deleterious or suspected deleterious gBRCA or HRR mutation status and prior chemotherapy or endocrine therapy as specified; missing this documentation risks denial.

    • Provide molecular reports and prior treatment history aligned with indication
    Denial Risk

    Topical acne — cosmetic use excluded

    Topical acne products will not be authorized for cosmetic purposes; ensure indication supports medical necessity before submitting a request.

    Denial Risk

    Rubraca — concurrent chemotherapy is excluded

    Rubraca will not be approved for concurrent use with other chemotherapy agents; do not submit requests for concurrent chemotherapy regimens.

    Denial Risk

    Rydapt — not approved as single-agent induction for AML

    Rydapt will not be approved as single-agent induction therapy for AML; authorization requires use in combination with standard induction agents per the product criteria.

    Denial Risk

    Rubraca concurrent-use exclusion reiterated

    Rubraca concurrent-use exclusion: do not request Rubraca when the patient is receiving other chemotherapy agents, as concurrent use is not approved.

    Denial Risk

    Rydapt exclusion reiterated — require combination induction use

    Rydapt exclusion reiterated: Rydapt is not approved as single-agent induction therapy for AML—ensure combination induction use is documented.

    Denial Risk

    TIRF exclusion — not covered for non-cancer pain

    Transmucosal immediate-release fentanyl (TIRF) products are not covered for any non-cancer pain indication; ensure submitted use is for cancer breakthrough pain in opioid-tolerant patients.

    Denial Risk

    TIRF — non-cancer pain coverage exclusion

    TIRF products will not be covered for any non-cancer pain indication—do not submit requests for non-cancer pain management.

    Step Therapy

    Voquezna prerequisite therapies — bismuth quadruple or two-PPI trials required

    Voquezna and Voquezna packs require trial and failure, contraindication, or intolerance to bismuth quadruple therapy for H. pylori; for HRH/MHRH/NERD require trial and inadequate response or intolerance to two generic PPIs—document prior therapy trials and outcomes.

    Denial Risk

    Incomplete documentation may trigger denial

    Requests lacking required medical information (e.g., diagnostic confirmation, mutation test, biopsy, or absence of disqualifying conditions) may be denied—include the full set of product-specified documents to reduce denial risk.

    Note
    NYHA Functional Class — ATTR‑CM reference
    NYHA Functional Class allowedDocumentation must show New York Heart Association (NYHA) Functional Class I, II, or III
    Context of useRequired as part of confirmatory evidence for transthyretin‑mediated amyloidosis with cardiomyopathy (ATTR‑CM)
    Prescriber requirementPrescribed by a cardiologist for initial and reauthorization requests
    Pre‑treatment serum IgE — Xolair dosing eligibility
    Serum IgE pre‑treatment range>= 30 IU/mL and <= 1,300 IU/mL
    IndicationPre‑treatment IgE requirement applies to omalizumab (Xolair) for IgE‑mediated asthma indications
    Prescriber specialtiesPrescribing physician must be an allergist, dermatologist, immunologist, otolaryngologist, or pulmonologist (as specified)
    Prescriber restrictionPrescribed by or in consultation with an infectious disease specialist or pulmonologist
    Non‑radiographic axial spondyloarthritis (nr‑axSpA)
    nr‑axSpA definitionActive non‑radiographic axial spondyloarthritis with objective signs of inflammation (e.g., elevated CRP and/or MRI sacroiliitis) without definitive radiographic structural sacroiliac joint damage
    Prior therapy requirementMinimum one‑month trial and failure, contraindication, or intolerance to two NSAIDs at maximally indicated doses
    Clinical evidenceObjective inflammation demonstrated by elevated CRP and/or MRI sacroiliitis
    Rapidly progressing ADPKD — Jynarque initiation
    Rapidly progressing ADPKD — clinical requirementDocumented diagnosis of rapidly progressing autosomal dominant polycystic kidney disease required for Jynarque initiation
    Liver monitoring at initiationIf receiving Jynarque ≤18 months: measure ALT, AST, and bilirubin prior to initiation, at 2 and 4 weeks after initiation, then monthly for first 18 months
    Longer‑term monitoringIf receiving Jynarque >18 months: measure ALT, AST, and bilirubin at least every 3 months; exclude significant liver impairment/injury
    Kalydeco‑responsive CFTR mutation — genotype definition
    Kalydeco‑responsive CFTR mutationA CFTR mutation shown to be responsive to ivacaftor (Kalydeco) based on clinical and/or in‑vitro assay data or detected by an FDA‑cleared CFTR mutation test (with verification when recommended)
    Genotype exclusionKalydeco is not effective for patients homozygous for the F508del CFTR mutation
    Age/formulation noteGranules formulation: member must be ≥1 month of age
    PAH confirmation — right heart catheterization
    PAH confirmation requirementPulmonary arterial hypertension must be documented and confirmed by right heart catheterization
    Prescriber restrictionPrescribing physician must be a cardiologist or pulmonologist
    Related conditionIncludes persistent/recurrent or inoperable CTEPH as applicable
    FGFR2 fusion/rearrangement — Lytgobi
    FGFR2 fusion/rearrangement definitionDocumented FGFR2 gene fusions or other rearrangements in intrahepatic cholangiocarcinoma required for Lytgobi use
    Prescriber restrictionPrescribed by or in consultation with an oncologist
    Treatment contextIndicated for previously treated, unresectable, locally advanced or metastatic disease
    MASH — Rezdiffra
    MASH definitionMetabolic dysfunction‑associated steatohepatitis (MASH), formerly known as NASH
    Disease staging requirementDiagnosis without cirrhosis and fibrosis stage F2 or F3 confirmed by specified biomarker/imaging or liver biopsy within past 12 months
    Metabolic risk factorPresence of ≥1 metabolic risk factor required (e.g., type 2 diabetes, hypertension, obesity)
    Opioid tolerant — TIRF definition
    Opioid‑tolerant definition (TIRF) — duplicate referencePatients taking around‑the‑clock opioid medicine equivalent to morphine 60 mg oral daily, fentanyl transdermal 25 mcg/hour, oxycodone 30 mg oral daily, hydromorphone 8 mg oral daily, or an equianalgesic opioid dose daily for a week or longer
    Clinical applicationUsed to determine eligibility for Transmucosal Immediate‑Release Fentanyl products for breakthrough cancer pain
    Requirement to remain on opioidsPatients must remain on around‑the‑clock opioids when taking fentanyl transmucosal
    NYHA Functional Class — ATTR‑CM (duplicate)
    NYHA Functional Class (duplicate)Required documentation that patient has NYHA Functional Class I, II, or III heart failure for ATTR‑CM coverage
    Confirmatory evidence optionsOne of: TTR mutation, tissue biopsy with histologic confirmation of TTR amyloid, or cardiac MRI/scintigraphy suggestive plus absence of light‑chain amyloidosis
    PrescriberPrescribed by a cardiologist for initial and reauthorization requests
    Biomarker‑positive tumors — documentation requirement
    Biomarker requirement — tumorsCoverage of targeted therapies requires documented tumor biomarker status when indicated (examples include ALK‑positive, ROS1‑positive, BRAF V600 mutation)
    Example applicationMolecular test documentation required for agents such as Lynparza, Tabrecta, Xalkori, etc.
    Prescriber specialtyPrescribing physician specialty often required (e.g., oncologist) when biomarker‑positive tumor criteria apply